Last updated: 2026-10-13 05:03:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Celcuity Inc. (CELC) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $65,92, with a market capitalisation of $3,32B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $45,03 to $151,02. This page covers its latest market performance, valuation, price trends and company information.
$3,32B | |
$67,40 | |
$151,02 | |
$4,03 | |
$67,94 | |
900,78K | |
1,25M | |
-- | |
$151,02 | |
$45,03 | |
-- | |
-- |
Celcuity Inc. (CELC) last closed at $67,94 as of 2026-10-12 23:31:00, unchanged from the previous close of $67,94.
During the latest regular trading session, CELC traded between $4,03 and $151,02, with a volume of 900,78K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Celcuity Inc. (CELC) moved from $75,13 to $65,92, representing a decline of 12,25% ($9,21).
The stock traded between $63,23 and $79,18 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,83 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19,7%
CELC is currently trading at $65,92, placing it 19,7% of the way from its 52-week low of $45,03 to its 52-week high of $151,02. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 155 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Celcuity Inc. (CELC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.